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Mitochondria are complex organelles that perform many key activities 
in the cell. They contain multiple copies 
of their own genome, which encodes 13 
proteins in humans and the transfer RNAs 
and ribosomal RNAs needed to translate 
them.1 Thus, almost all of the hundreds of 
proteins needed for their function must 
be encoded in the nucleus and imported 
across the mitochondrial membranes. 
Within the mitochondria they undergo 
proteolytic processing and targeting to 
multiple compartments and enzyme com-
plexes.2 There are numerous diseases aris-
ing from mutations or defects in either the 
mitochondrial genome or those nuclear 
encoded and targeted proteins. These dis-
orders typically have serious health conse-
quences, and there are currently no cures 
for these mitochondrial disorders.
Repair of mitochondrial disorders is 
necessarily more complex than replacement 
of a cytosolic gene product and must take 
into account not only the need to target and 
cross multiple membranes in mitochon-
dria but also the fact that many enzymes 
in mitochondria are hydrophobic and not 
readily soluble. Additionally, many of the 
mitochondrial gene defects cause severe 
neurologic symptoms as the primary, or 
most prominent, phenotype, and drug deliv-
ery across the blood–brain barrier is notori-
ously difficult.3 As a result, current therapies 
for mitochondrial defects focus primarily 
on the use of small molecules to enhance 
flux through the electron transport chain, 
such as with coenzyme Q for OXPHOS 
diseases,4 or altering the precursor pool of 
substrate to avoid the defective metabolic 
pathway, such as changing dietary intake 
of fatty acids to avoid medium-chain lipids 
in medium-chain acyl-dehydrogenase defi-
ciency.5 Thus far, neither gene therapy nor 
enzyme-replacement therapy (ERT) has 
been accomplished for mitochondrial de-
fects, much less to correct a defect across the 
blood–brain barrier. However, in this issue 
of Molecular Therapy, Rapoport et al. seem 
to have taken an important step toward this 
difficult goal.6
In their report the authors use the pro-
tein transactivator of transcription (TAT) 
domain to deliver lipoamide dehydrogenase 
(LAD) to mitochondria in fibroblasts from 
patients suffering from LAD deficiency. 
Rapoport and coworkers convincingly dem-
onstrated that TAT could transduce the 
LAD protein across the cell and mitochon-
drial membranes. Furthermore, this trans-
duced enzyme appears to be able to replace 
the defective enzyme in a large multisubunit 
complex to restore near-normal enzymatic 
function. LAD is the third catalytic subunit 
(E3) of three multicomponent enzymatic 
complexes (α-ketoacid dehydrogenase com-
plexes) in the mitochondrial matrix that are 
crucial for the metabolism of carbohydrates 
and amino acids.7 The α-ketoacid dehy-
drogenase complexes consist of pyruvate 
dehydrogenase complex, α-ketoglutarate 
dehydrogenase complex, and the branched-
chain ketoacid dehydrogenase complex.7,8 A 
mutation of the LAD gene leads to altera-
tion of the normal activity of α-ketoacid de-
hydrogenase complexes, resulting in lactic 
acidemia, dysfunction of the Krebs cycle, 
and impaired branched-chain amino acid 
degradation. These are serious metabolic 
disruptions, and patients with this disease 
can present with severe neurological symp-
toms in infancy, or recurrent episodes of 
liver failure or myoglobinuria that can be 
fatal.9,10 Thus, there is a significant human 
health impact to developing ERT for this 
disease, as well as establishing a model for 
other mitochondrial disease therapies.
TAT is a short cationic peptide derived 
from the larger TAT protein of HIV that 
has cell-penetrating properties.11−13 Cell-
penetrating peptides are typically small 
cationic peptides that can transport a cargo 
of molecules, such as proteins, peptides, or 
oligonucleotides, into cells that otherwise 
could not absorb large-molecular-weight 
compounds. Various transduction peptides 
such as polyarginine, synB5, antennapedia, 
and herpes simplex virus type I protein have 
been used to transport complex proteins 
into cells and have thereby shown promise 
as therapeutic strategies for several disease 
conditions.14−17 This is important because de-
livery of drugs and therapeutic compounds 
is primarily limited by their ability to pen-
etrate the cell membrane. The bioavailability 
of compounds targeted to intracellular sites 
depends on the conflicting requirements of 
being sufficiently polar for administration 
and distribution, yet nonpolar enough to 
diffuse through the nonpolar lipid bilayer of 
the cell.3 In addition, the molecular weight 
of most drugs that can easily traverse the 
lipid membrane is approximately 500 Da.18 
Thus, most successful compounds have nar-
row physical characteristics. Many promis-
ing drugs fail because they fall outside this 
range, and efforts to make them available 
may be toxic. In addition to this, many sites 
of action for presumed therapeutic com-
pounds, such as enzymes or regulatory 
proteins, require processing and targeting 
of the compound once inside the cell. This 
step alone represents a significant hurdle to 
the development of many strategies to repair 
defects within a cell. Cell-penetrating pep-
tides offer exciting potential to overcome 
many of these problems for ERT.
Rapoport et al. took advantage of the 
native mitochondrial targeting sequence for 
LAD (TAT-LAD)7 and showed that it was 
necessary for maximal restoration of LAD 
enzymatic function. Deleting the mito-
chondrial targeting sequence (TAT-∆-LAD) 
restored a significantly smaller amount 
of LAD activity within the mitochondria. 
This is a subtle but important point to con-
sider: TAT can move both ways across a 
membrane and thus pull the therapeutic 
cargo out of the mitochondria. With the 
mitochondrial targeting sequence included, 
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the matrix processing peptidases recognize 
the sequence and clip it, and the cargo (ma-
ture LAD) is left in the matrix while the TAT 
peptide can transduce out of the mitochon-
drion (Figure 1). Repeated dosing should 
therefore result in accumulating amounts 
of cargo in the mitochondria over time. A 
similar strategy might be used for other 
organelles, such as the nucleus, where in-
corporation of a nuclear localization signal 
(NLS) would increase transduction of a TAT 
fusion protein into the nucleus.
TAT is capable of transducing single 
components of very large enzyme complexes 
to restore activity of the native complex. The 
authors clearly demonstrate that TAT-LAD 
can substitute for the mutated LAD enzyme 
within the pyruvate dehydrogenase com-
plex and restore its activity to almost normal 
levels. Proteins are normally imported into 
mitochondria in denatured form,19 and mi-
tochondria are thus well equipped to refold 
proteins into an active configuration for in-
corporation with larger enzyme complexes. 
Because cell-penetrating peptides depend 
on the fusion protein’s being sufficiently 
denatured to make the penetrating peptide 
available to initiate transduction, protein-
transduction technology is perfectly suited 
for ERT in mitochondria.
The authors also found that it was not 
necessary to restore all the missing protein 
to restore adequate amounts of enzymatic 
activity in mitochondria. This is important 
for point mutations that have a dominant-
negative impact on a larger enzyme complex. 
Small amounts of normal protein may be 
adequate to repair the defect. This concept is 
also important for organs in which it is typi-
cally difficult to deliver drugs, such as the 
brain or placenta. TAT has been shown to 
cross the blood–brain barrier and placenta 
quite well.11,20,21 This opens the possibility of 
initiating ERT for mitochondrial defects be-
fore birth, or for neurological disorders that 
manifest well after birth.
ERT had not been accomplished for a 
mitochondrial defect before this new re-
port, although it is an established therapy 
for other metabolic disorders, such as the 
lysosomal diseases of Hurler’s syndrome 
and Pompe’s disease. TAT has been used to 
replace missing enzymes in animal models 
of disease, such as purine nucleoside phos-
phorylase,15 and has delivered a variety of 
exogenous proteins to cytosolic and mito-
chondrial locations. Thus, it was a logical 
extension of these earlier findings that TAT 
can deliver a mitochondrial therapeutic 
cargo. Rapoport and colleagues are to be 
acknowledged for opening the door even 
further for the use of TAT as a potential 
treatment strategy for a difficult set of mi-
tochondrial diseases. Although protein-
transduction technology is still a basic tool 
at this time, it is virtually certain to advance 
rapidly in the future as better and more effi-
cient transduction domains are discovered 
and the mechanism(s) for protein trans-
duction are better understood.
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Figure 1 Site-specific delivery of TAT-conjugated proteins. A TAT fusion protein containing 
either a mitochondrial targeting sequence (TAT-MTS fusion protein) or a nuclear localization signal 
(TAT-NLS fusion protein) can transduce into a cell. If the protein transduces into the mitochondria 
and contains a MTS, the mitochondrial processing peptidases will recognize the MTS and clip it, 
leaving the protein in the mitochondrial matrix. The TAT-MTS peptide will transduce out of the 
mitochondria. Although the nucleus does not have processing peptidases that recognize the NLS 
sequence, the presence of this sequence should increase the frequency of transduction of the TAT 
fusion protein into the nucleus.
